Evidence that selenium affects CHD risk is equivocal, despite a good biological rationale for a beneficial effect of optimal selenoprotein activity and concentration. However, concern has surfaced recently about possible associations of high selenium exposure with cardiometabolic risk. A number of sizeable cross-sectional analyses have shown an association between high selenium status in adults and elevated serum or plasma concentrations of total, LDL and non-HDL cholesterol (1-3) , but there is virtually no data from randomized clinical trials on the effect of selenium supplementation on plasma lipids.
In view of the potential public-health implications of hyperlipidaemia and the widespread use of selenium-containing supplements, the results are reassuring. However, because of the relatively low baseline Se status of the population, the short duration of the intervention and the limited range of the age group involved (60-74 years), additional trials are needed to establish whether these results are more widely applicable. The full range of cardio-metabolic effects of selenium and its potential role in the prevention of CVD need to be further explored.
